Using AMG900 to Treat Breast Cancer


Richard S. Finn, MD, discusses the aurora kinase inhibitor AMG900.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the aurora kinase inhibitor AMG900.

Clinical Pearls

  • AMG900 is a small molecule inhibitor of aurora kinases, which are proteins that are involved in maintaining DNA integrity and controlling DNA replication
  • AMG900 has been evaluated in breast cancer models to try to determine which group of patients will benefit
  • Results of an AMG900 trial showed that patients with p53 mutation may have a potential benefit with the agent
  • p53 mutations are common throughout all the molecular subtypes of breast cancer but triple-negative breast cancer (TNBC) shows a higher frequency of these mutations
  • This early preclinical work suggests that p53 mutations may act as a biomarker for selecting patients who will benefit from AMG900
  • AMG900 is now in a phase I study that includes patients with TNBC and a biomarker component will be included in the study to help researchers get a better understanding of how the drug is working
Related Videos
Video 6 - "Current Approaches to Treatment Sequencing in HER2+ Breast Cancer"
Video 5 - "Exciting Developments in HER2+ Breast Cancer"
Video 4 - "KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer"
Video 3 - "APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer"
Rebecca A. Shatsky, MD, an expert on breast cancer
Related Content